Psychotropic-induced weight gain and potential pharmacologic treatment strategies.
作者信息
Gracious Barbara L, Meyer Ashley E
机构信息
Dr. Gracious is Assistant Professor of Psychiatry and Obstetrics and Gynecology, at the University of Rochester Medical Center.
出版信息
Psychiatry (Edgmont). 2005 Jan;2(1):36-42.
Abstract
摘要
相似文献
1
Psychotropic-induced weight gain and potential pharmacologic treatment strategies.精神药物所致体重增加及潜在的药物治疗策略。
Psychiatry (Edgmont). 2005 Jan;2(1):36-42.
2
[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].[精神药物所致体重增加：关于流行病学数据、机制及管理的文献综述]
Encephale. 2005 Jul-Aug;31(4 Pt 1):507-16. doi: 10.1016/s0013-7006(05)82412-1.
3
Nursing considerations in psychotropic medication-induced weight gain.精神药物所致体重增加的护理考量
Clin Nurse Spec. 2004 Mar-Apr;18(2):80-7. doi: 10.1097/00002800-200403000-00013.
4
Weight gain associated with taking psychotropic medication: an integrative review.服用精神类药物导致的体重增加：综合述评。
Int J Ment Health Nurs. 2011 Jun;20(3):202-22. doi: 10.1111/j.1447-0349.2010.00721.x. Epub 2011 Feb 18.
5
Double jeopardy: a review of weight gain and weight management strategies for psychotropic medication prescribing during methadone maintenance treatment.双重困境：美沙酮维持治疗期间精神药物处方中体重增加和体重管理策略的综述。
Int Rev Psychiatry. 2018 Oct;30(5):147-154. doi: 10.1080/09540261.2018.1509843. Epub 2018 Nov 6.
6
Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients.精神药物诱导的 CRTC1 基因遗传-表观遗传调控与精神科患者前瞻性研究中的早期体重增加有关。
Clin Epigenetics. 2019 Dec 26;11(1):198. doi: 10.1186/s13148-019-0792-0.
7
[The physiopathology of weight regulation during treatment with psychotropic drugs].[精神药物治疗期间体重调节的生理病理学]
Fortschr Neurol Psychiatr. 2001 Mar;69(3):116-37. doi: 10.1055/s-2001-12278.
8
Psychotropic drug induced weight gain: mechanisms and management.精神药物所致体重增加：机制与管理
Clin Neuropharmacol. 1988;11 Suppl 1:S194-206.
9
Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications.抗精神病药物治疗患者体重增加和代谢紊乱的药物及非药物策略。
Can J Psychiatry. 2006 Jul;51(8):502-11. doi: 10.1177/070674370605100805.
10
Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment.早期体重变化对预测精神药物治疗期间长期体重增加的重要性。
J Clin Psychiatry. 2015 Nov;76(11):e1417-23. doi: 10.4088/JCP.14m09358.
引用本文的文献
1
Amitriptyline increases food intake via prdx-2 without altering other physiological parameters in C. elegans under a modified bacterial diet.在改良细菌饮食条件下，阿米替林通过prdx-2增加线虫的食物摄入量，而不改变其他生理参数。
Sci Rep. 2025 Aug 11;15(1):29428. doi: 10.1038/s41598-025-14773-8.
2
Determinants of Kidney Function and Accuracy of Kidney Microcysts Detection in Patients Treated With Lithium Salts for Bipolar Disorder.锂盐治疗双相情感障碍患者的肾功能决定因素及肾微囊肿检测准确性
Front Pharmacol. 2022 Jan 7;12:784298. doi: 10.3389/fphar.2021.784298. eCollection 2021.
3
Synergistic Effects of Psychotropics Leading to Extraordinary Weight Gain.精神药物的协同作用导致显著体重增加。
Cureus. 2021 Sep 14;13(9):e17978. doi: 10.7759/cureus.17978. eCollection 2021 Sep.
4
The Pharmacological Activity of (L.) Kuntze on Metabolic and Endocrine Disorders: A Systematic Review.（L.）昆特对代谢和内分泌紊乱的药理活性：系统评价。
Biomolecules. 2020 Apr 13;10(4):603. doi: 10.3390/biom10040603.
5
Obesity in adults with 22q11.2 deletion syndrome.患有22q11.2缺失综合征的成年人肥胖症
Genet Med. 2017 Feb;19(2):204-208. doi: 10.1038/gim.2016.98. Epub 2016 Aug 18.
6
Metformin for Lithium-induced Weight Gain: A Case Report.二甲双胍治疗锂盐所致体重增加：一例报告
Clin Psychopharmacol Neurosci. 2016 Feb 29;14(1):101-3. doi: 10.9758/cpn.2016.14.1.101.
7
Assessing obesity and other related health problems of mentally ill Hispanic patients in an urban outpatient setting.在城市门诊环境中评估患有精神疾病的西班牙裔患者的肥胖及其他相关健康问题。
Psychiatr Q. 2007 Sep;78(3):171-81. doi: 10.1007/s11126-007-9038-y.
本文引用的文献
1
The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease.肥胖症的男性化程度：决定糖尿病、动脉粥样硬化、痛风和尿酸结石病易感性的一个因素。
Am J Clin Nutr. 1956 Jan-Feb;4(1):20-34. doi: 10.1093/ajcn/4.1.20.
2
Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994.青少年代谢综合征表型的患病率：1988 - 1994年第三次全国健康和营养检查调查结果
Arch Pediatr Adolesc Med. 2003 Aug;157(8):821-7. doi: 10.1001/archpedi.157.8.821.
3
Obesity: burdens of illness and strategies for prevention or management.肥胖：疾病负担与预防或管理策略
Drugs Today (Barc). 2000 Nov;36(11):773-84. doi: 10.1358/dot.2000.36.11.601531.
4
Valproate, bipolar disorder and polycystic ovarian syndrome.丙戊酸盐、双相情感障碍与多囊卵巢综合征。
Bipolar Disord. 2003 Feb;5(1):28-35. doi: 10.1034/j.1399-5618.2003.00009.x.
5
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial.尼扎替丁预防奥氮平所致体重增加：一项双盲安慰剂对照试验。
Eur Neuropsychopharmacol. 2003 Mar;13(2):81-5. doi: 10.1016/s0924-977x(02)00127-x.
6
Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series.金刚烷胺治疗儿童和青少年精神药物所致体重增加：病例系列
J Child Adolesc Psychopharmacol. 2002 Fall;12(3):249-57. doi: 10.1089/104454602760386941.
7
Weight gain and serum leptin levels in patients on lithium treatment.锂盐治疗患者的体重增加及血清瘦素水平
Neuropsychobiology. 2002;46(2):67-9. doi: 10.1159/000065414.
8
Metformin for weight loss in pediatric patients taking psychotropic drugs.二甲双胍用于服用精神药物的儿科患者减肥。
Am J Psychiatry. 2002 Apr;159(4):655-7. doi: 10.1176/appi.ajp.159.4.655.
9
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.通过生活方式干预或二甲双胍降低2型糖尿病的发病率。
N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512.
10
Drug treatment of obesity.肥胖症的药物治疗
Rev Endocr Metab Disord. 2001 Oct;2(4):403-18. doi: 10.1023/a:1011808701117.
Zotero 插件